This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spruance, S. L. Articles by Spaulding, T. Search for Related Content PubMed PubMed Citation Articles by Spruance, S. L. Articles by Spaulding, T.

Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials

Division of Infectious Diseases, University of Utah, Salt Lake City, Utah,¹ San Antonio Center for Clinical Research, San Antonio, Texas,² Orlando Clinical Research Center, Orlando Florida,³ St. Louis Pharmaceutical Research, Inc., St. Louis, Missouri,⁴ GlaxoWellcome Inc., Research Triangle Park, North Carolina⁵

Received 20 August 2001/ Returned for modification 29 January 2002/ Accepted 8 April 2002

Acyclovir cream has been available for the treatment of herpes labialis in numerous countries outside the United States for over a decade. Evidence for its efficacy comes from a few small clinical trials conducted in the 1980s. To examine more comprehensively the efficacy and safety of this formulation, we conducted two independent, identical, parallel, randomized, double-blind, vehicle-controlled, large-scale multicenter clinical trials. Healthy adults with a history of frequent herpes labialis were recruited from the general population, screened for eligibility, randomized equally to 5% acyclovir cream or vehicle control, given study medication, and told to self-initiate treatment five times daily for 4 days beginning within 1 h of the onset of a recurrent episode. The number of patients who treated a lesion was 686 in study 1 and 699 in study 2. In study 1, the mean duration of episodes was 4.3 days for patients treated with acyclovir cream and 4.8 days for those treated with the vehicle control (hazards ratio [HR] = 1.23; 95% confidence interval [CI], 1.06 to 1.44; P = 0.007). In study 2, the mean duration of episodes was 4.6 days for patients treated with acyclovir cream and 5.2 days for those treated with the vehicle control (HR = 1.24; 95% CI, 1.06 to 1.44; P = 0.006). Efficacy was apparent whether therapy was initiated "early" (prodrome or erythema lesion stage) or "late" (papule or vesicle stage). There was a statistically significant reduction in the duration of lesion pain in both studies. Acyclovir cream did not prevent the development of classical lesions (progression to vesicles, ulcers, and/or crusts). Adverse events were mild and infrequent.

This article has been cited by other articles:

• Cernik, C., Gallina, K., Brodell, R. T. (2008). The Treatment of Herpes Simplex Infections: An Evidence-Based Review. Arch Intern Med 168: 1137-1144 [Abstract] [Full Text]  
• Jensen, L. A, Hoehns, J. D, Squires, C. L (2004). Oral Antivirals for the Acute Treatment of Recurrent Herpes Labialis. The Annals of Pharmacotherapy 38: 705-709 [Abstract] [Full Text]  
• Spruance, S. L., Jones, T. M., Blatter, M. M., Vargas-Cortes, M., Barber, J., Hill, J., Goldstein, D., Schultz, M. (2003). High-Dose, Short-Duration, Early Valacyclovir Therapy for Episodic Treatment of Cold Sores: Results of Two Randomized, Placebo-Controlled, Multicenter Studies. Antimicrob. Agents Chemother. 47: 1072-1080 [Abstract] [Full Text]  
• Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., Sutton, D. (2003). Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy. Clin. Microbiol. Rev. 16: 114-128 [Abstract] [Full Text]